Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch–2-Year Follow-Up

Because of the shortage of agalsidase-β supply between 2009 and 2012, patients with Fabry disease either were treated with reduced doses or were switched to agalsidase-α. In this observational study, we assessed end organ damage and clinical symptoms with special focus on renal outcome after 2 years...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:J Am Soc Nephrol
Κύριοι συγγραφείς: Lenders, Malte, Canaan-Kühl, Sima, Krämer, Johannes, Duning, Thomas, Reiermann, Stefanie, Sommer, Claudia, Stypmann, Jörg, Blaschke, Daniela, Üçeyler, Nurcan, Hense, Hans-Werner, Brand, Stefan-Martin, Wanner, Christoph, Weidemann, Frank, Brand, Eva
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society of Nephrology 2016
Θέματα:
Clinical Research
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4769208/
https://ncbi.nlm.nih.gov/pubmed/26185201
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2015030337
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια